{"id":143,"date":"2026-09-04T05:30:40","date_gmt":"2026-09-04T05:30:40","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=143"},"modified":"2026-09-04T05:30:40","modified_gmt":"2026-09-04T05:30:40","slug":"synthesis-of-iberdomide-zenbexus-drug-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/synthesis-of-iberdomide-zenbexus-drug-intelligence-dossier\/","title":{"rendered":"Synthesis of Iberdomide (ZENBEXUS) \u2014 Drug Intelligence Dossier"},"content":{"rendered":"\n

Mechanism:<\/strong>\u00a0Iberdomide is a potent, orally available cereblon (CRBN) E3 ligase modulator (CELMoD). It binds CRBN \u2014 the substrate receptor of the CRL4^CRBN E3 ubiquitin ligase \u2014 and reshapes the substrate-recruitment surface to drive ubiquitination and proteasomal degradation of the myeloma-survival transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos). Relative to the first-generation IMiDs lenalidomide and pomalidomide, iberdomide binds CRBN with ~20-fold higher affinity (reported CRBN-binding IC50 ~150 nM), giving deeper\/more complete Ikaros-Aiolos degradation and retained activity in lenalidomide\/pomalidomide-resistant myeloma cells with dysregulated CRBN. Downstream effects are dual: direct anti-myeloma (apoptosis, suppression of the IRF4\/MYC axis) plus immunomodulatory T-cell and NK-cell co-stimulation, with preclinical synergy alongside dexamethasone, proteasome inhibitors and anti-CD38 antibodies. The CRBN-DDB1-CC-220 co-crystal structure (Matyskiela et al., 2018) shows the morpholinomethyl-benzyloxy arm making additional cereblon contacts away from the Ikaros\/Aiolos interface, rationalising the affinity gain. Refs: PMID 28425720 (crystal\/medchem), PMID 29945920 (Ikaros\/Aiolos PD).<\/p>\n\n\n\n

t\u00bd:<\/strong>\u00a0Terminal t\u00bd ~9-13 h (single dose) \u2014 supports once-daily dosing on the 21-of-28-day schedule \u00b7\u00a0Tmax:<\/strong>\u00a0Oral; absorbed with a Tmax of a few hours [VERIFY vs label \u00a712.3]<\/p>\n\n\n\n

Synthesis Route of the Originator<\/h2>\n\n\n\n

Disclosed kilogram-scale process (Zacuto et al., Org. Process Res. Dev. 2024, 28(1), 46-56 and 57-66) reconstructed at the level of disclosed building blocks and step order. Three fragments converge from the L-glutamine chiral pool. Methyl 3-hydroxybenzoate is Duff-formylated ortho to the phenol to the salicylaldehyde ester (INT-A1); Williamson O-alkylation with 4-(morpholinomethyl)benzyl chloride (from selective mono-alkylation of 1,4-bis(chloromethyl)benzene with morpholine) installs the benzyl ether (INT-A2). Reductive amination of the aldehyde with L-glutamine tert-butyl ester followed by intramolecular lactamisation builds the 1-oxoisoindoline (INT-A3), carrying the open glutaramide. Finally, tert-butyl ester cleavage and glutarimide (imide) ring closure \u2014 deliberately the LAST step, run under controlled conditions to protect the labile (S) C3 centre \u2014 give iberdomide, isolated as the hydrochloride. STEREO: the single (S) stereocentre traces from L-glutamine (2S) with retention throughout; <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n

a<\/sup>Reagents and conditions: (1) Hexamethylenetetramine (HMTA), acid (AcOH\/TFA), heat \u2014 regioselective ortho-formylation between the phenol and the ester to give the salicylaldehyde ester.; (2) 4-(morpholinomethyl)benzyl chloride (BB3, 1.0-1.1 eq; from mono-alkylation of 1,4-bis(chloromethyl)benzene [CAS 623-25-6] with morpholine [CAS 110-91-8]), K2CO3, DMF or MeCN, 50-80 \u00b0C. Controlled stoichiometry on BB3 formation avoids the bis-morpholino impurity.; (3) L-glutamine tert-butyl ester (BB1, H-Gln-OtBu; CAS 39741-62-3 as HCl salt), NaBH(OAc)3 or NaBH4 (chemoselective imine reduction sparing the aryl ester), then intramolecular lactamisation (benzylamine onto the aryl ester \u2192 1-oxoisoindoline). Sets\/retains (S) from the L-glutamine chiral pool.; (4) Acid (TFA or HCl) removes the tert-butyl ester; the liberated alpha-acid cyclises onto the gamma-primary amide to close the piperidine-2,6-dione (glutarimide) under CDI or thermal\/coupling conditions. Run LAST and under controlled conditions (OPRD Part 2) to preserve the labile (S) C3 stereocentre. Free base C25H27N3O5, MW 449.51.; (5) The marketed ZENBEXUS drug substance is iberdomide hydrochloride (C25H27N3O5\u00b7HCl; per FDA label DESCRIPTION). Treat the free base with HCl in a suitable solvent and crystallise. (The OPRD process papers developed the besylate\/BSA salt as an isolation\/process form; the registered form is the HCl.).<\/p>\n\n\n\n

Key intermediates<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Crystal Forms, Salts, and Solid-State Profile<\/h2>\n\n\n\n